Grifols announced the launch of a new 3mL (900 IU) vial of HyperRAB® (rabies immune globulin [human]) for rabies postexposure prophylaxis.
According to the Company, the 3mL vial size may potentially reduce the number of vials used during administration, thereby cutting product and package waste. HyperRAB for intramuscular injection is now available in 3 sizes: 1mL (300 IU), 3mL (900 IU) and 5mL (1500 IU) single-dose vials.
“With the higher-potency product, our patients already benefit from a significant reduction in the volume of medication administered in each dose,” said Evelyn Chu, Director of Pharmacy, Henderson Hospital, owned by Universal Health Services. “Now with the introduction of an intermediate vial size to our inventory, it will bring us additional operational efficiencies in the pharmacy.”
To be effective, HyperRAB should be used in combination with rabies vaccine; it should not be used alone for prevention. Currently, the Advisory Committee on Immunization Practices (ACIP) recommends individuals who have not been previously vaccinated receive immediate prophylaxis upon exposure to rabies, including a rabies immune globulin injection directly into the wound site to prevent the virus from entering the central nervous system.
For more information visit hyperrab.com.
This article originally appeared on MPR